Bioactivation of N-substituted N′-(4-imidazole-ethyl)thioureas by human FMO1 and FMO3

Xenobiotica

Volumn 36, Issue 7, 2006, Pages 645-657

  Onderwater, R C A ^a   Rettie, A E ^b   Commandeur, J N M ^a   Vermeulen, N P E ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Bioactivation; Human FMO1; Human FMO3; Sulfenic acids; Thiocholine; Thiourea

Indexed keywords

DIMETHYLANILINE MONOOXYGENASE; N ETHYL N' (4 IMIDAZOLETHYL)THIOUREA; THIOCHOLINE; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CORRELATION ANALYSIS; DRUG ACTIVATION; ELECTRON; ENZYME KINETICS; LIVER MICROSOME; METHODOLOGY; OXIDATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; BIOTRANSFORMATION; HUMANS; IMIDAZOLES; OXYGENASES; RATS; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; THIOUREA;

EID: 33746844053     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250500354329     Document Type: Article

References (25)

1. Cantrell AS, Engelhardt P, Högberg M, Jaskunas SR, Gunnar Johansson N, Jordan CL, Kangasmetsä J, Kinnick MD, Lind P, Morin Jr JM, Muesing MA, Noreén R, Öberg B, Pranc P, Sahlberg C, Ternansky RJ, Vasileff RT, Vrang L, West SJ, Zhang H. 1996. Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further strucure-activity relationship studies of PETT analogs. Journal of Medical Chemistry 39:4261-4274.
2. Cashman JR. 2000. Human flavin-containing monooxygenase: substrate specificity and role in drug metabolism. Current Drug Metabolism 1:181-191.
3. Cashman JR, Hanzlik RP. 1982. Oxidation and other reactions of thiobenzamide derivatives of relevance to their hepatotoxicity. Journal of Organic Chemistry 47:4645-4650.
4. Cherrington NJ, Cao Y, Cherrington JW, Rose RL, Hodgson E. 1998. Physiological factors affecting protein expression of flavin-containing monooxygenases 1, 3 and 5. Xenobiotica 28:673-682.
5. D'Cruz OJ, Dong Y, Uckun FM. 2003. Potent dual anti-HIV and spermicidal activities of novel oxovanadium(V) complexes with thiourea non-nucleoside inhibitors of HIV-1 reverse transcriptase. Biochemical and Biophysical Research Communications 302:253-264.
6. D'Cruz OJ, Venkatachalam TK, Mao C, Qazi S, Uckun FM. 2002. Structural requirements for potent antihuman immunodificiency virus (HIV) and sperm-immobilizing activities of cyclohexenyl thiourea and urea non-nucleoside inhibitors of HIV-1 reverse transcriptase. Biology and Reproduction 67:1959-1974.
7. Doerge DR, Corbett MD. 1984. Primary amine oxidation by a flavinhydroperoxide. A study of the basis for the substrate specificity of the flavoprotein monooxygenase. Biochemistry and Pharmacology 33:3615-3619.
8. Forrest JAH, Shearman DJC, Spence R, Celestin LR. 1975. Neutropenia associated with metiamide. Lancet 0:392-393.
9. Guo W-XA, Poulsen LL, Ziegler DM. 1992. Use of thiocarbamides as selective substrate probes for isoforms of flavin-containing monooxygenases. Biochemistry and Pharmacology 44:2029-2037.
10. Guo W-XA, Ziegler DM. 1991. Estimation of flavin-containing monooxygenase activities in crude tissue preparations by thiourea dependent oxidation of thiocholine. Annals of Biochemistry 198:143-148.
11. Henderson MC, Krueger SK, Stevens JF, Williams DE. 2004. Human flavin-containing monooxygenase form 2 S-oxygenation: sulfenic acid formation from thioureas and oxidation of glutathione. Chemical Research in Toxicology 17:633-640.
12. Hernandez D, Janmohamed A, Chandan P, Phillips IR, Shephard EA. 2004. Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters. Pharmacogenetics 14:117-130.
13. Högberg M, Morrison I. 2000. HIV-1 non-nucleoside reverse transcriptase inhibitors. Experimental Opinions Therapy Patents 10:1189-1199.
14. Kim YM, Ziegler DM. 2000. Size limits of thiocarbamides accepted as substrates by human flavin-containing monooxygenase. Drug Metabolism and Disposition 28:1003-1006.
15. Lang DH, Yeung CK, Peter RM, Ibarra C, Gasser R, Itagaki K, Philpot RM, Rettie AE. 1998. Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3. Biochemistry and Pharmacology 56:1005-1012.
16. Nagata T, Williams DE, Ziegler DM. 1990. Substrate specificities of rabbit lung and porcine liver flavin-containing monooxygenases: differences due to substrate size. Chemical Research in Toxicology 3:372-376.
17. Onderwater RCA, Commandeur JNM, Groot EJ, Sitters A, Menge WMPB, Vermeulen NPE. 1998. Cytotoxicity of a series of mono- and di-substituted thiourea in freshly isolated rat hepatocytes: a preliminary structuretoxicity relationship study. Toxicology 125:117-129.
18. Onderwater RCA, Commandeur JNM, Menge WMPB, Vermeulen NPE. 1999. Activation of microsomal glutathione S-transferase and inhibition of cytochrome P450 1A1 activity as a model system to detect protein alkylation by thiourea-containing compounds in rat liver microsomes. Chemical Research in Toxicology 12:396-402.
19. Onderwater RCA, Commandeur JNM, Vermeulen NPE. 2004. Comparative cytotoxicity of N-substituted N′-(4-imidazole-ethyl)thiourea towards precision-cut rat liver slices. Toxicology 197:81-91.
20. Poulsen LL, Hyslop RM, Ziegler DM. 1979. S-Oxygenation of N-substituted thioureas catalyzed by the pig liver microsomal FAD-containing monooxygenase. Archives in Biochemisty and Biophysics 198:78-88.
21. Poulsen LL, Ziegler DM. 1995. Multisubstrate flavin-containing monooxygenases: applications of mechanism to specificity. Chemico-Biology Interactions 96:57-73.
22. Shehin-Johnson SE, Williams DE, Larsen-Su S, Stresser DM, Hines RN. 1995. Tissue-specific expression of flavin-containing monooxygenase (FMO) forms 1 and 2 in the rabbit. Journal of Pharmology and Experimental Therapy 272:1293-1299.
23. Smith PB, Crespi C. 2002. Thiourea toxicity in mouse C3H/10T1/2 cells expressing human flavin dependent monooxygenase 3. Biochemistry and Pharmacology 63:1941-1948.
24. Vollinga RC, Menge WMPB, Leurs R, Timmerman H. 1995. New analogs of burimamide as potent and selective histamine H3 receptor antagonists: the effect of chain length variation of the alkyl spacer and modifications of the N-thiourea substituent. Journal of Medical Chemistry 38:2244-2250.
25. Ziegler DM. 2002. An overview of the mechanism, substrate specificities, and structure of FMOs. Drug Metabolism Reviews 34:503-511.